Recent

% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

nammuang 273 posts  |  Last Activity: 8 hours ago Member since: Jun 26, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Do yourself a favor and ask your mum to confiscate your computer. See a shrink. No one reads your one liners except when forced to during a page refresh. You are on IGNORE by everyone and his Dog.
    But even so your endless meaningless posts take up a lot of greyed out space here.
    Try to get some real friends in the real world to communicate with instead of communicating AT, not with a bunch of ID's on a board that you do not know. Seek Help.

  • Reply to

    Epipen, Whats the confusion?

    by icantrade200 Jan 12, 2016 10:20 PM
    nammuang nammuang Jan 12, 2016 10:41 PM Flag

    whogo icantrade gaspasser,
    Why would you have a copy of the Mylan injector instructions with you when you take the Teva injector out of the package. Would you not check on the instructions that cams with what you are holding in your hand?

  • Reply to

    I hate to mention this

    by icantrade200 Nov 20, 2015 9:29 AM
    nammuang nammuang Nov 20, 2015 10:03 AM Flag

    Whogo,
    The suicide was interesting, The guy actually stood on the injector and leaped to his death. He was wearing Nike running shoes. Due to this unfortunate event all Antares injectors and all Nike footwear will be banned.

  • OTREXUP is Slowly but Surely edging towards profitability.
    Ferring is preparing for an imminent GLOBAL launch of ZOMA-Jet™.
    Suma FDA A/B Generic approved and will be released mid year Sold by TEVA on a 50/50 profit split.
    QST FDA NDA FILING ANTICIPATED THIS YEAR.
    EPI A/B APPROVAL AND LAUNCH ANTICIPATED THIS YEAR.
    #
    And here we are at 1.08 Dollar per share?

  • Reply to

    checking in --

    by tappyt_2014 Jan 20, 2016 9:13 PM
    nammuang nammuang Jan 21, 2016 7:28 AM Flag

    Ryman,
    At the end Q3 they had 50MM cash on hand that's at least 10Q with decreasing burn rate considering OTREXUP going up(flat last Q) Probable increase in injector sales with added second line at the beginning of Q4. Hopefully meaninful increase in Otrexup sales(December indicator+company statement) Sumatriptan launch Jul1....... and be and behold EPI the big elephant in the room. they will surely be making money by the end of the year with just OTREXUP and SUMA

  • The only one that can comment on any CRL to Teva is obviously Teva. Regardless of whats in the CRL if there is one, no other entity can comment on it's content unless Teva does so. I don't understand how you people can expect that ATRS somehow should be in a position to say anything since nothing has come out from Teva. EPI is a TEVA Product.

  • Reply to

    Teva EPI CRL or Not

    by nammuang Jan 5, 2016 6:53 PM
    nammuang nammuang Jan 5, 2016 7:58 PM Flag

    Whigo,
    Who is lying about what? What he said was that there is no injector problem. If there would be Teva would surely have told them but that does not seem to be the case. Apparently there is no injector problem according to Howarth, do you have a problem with that? Where is the lie?

  • Reply to

    Dr Reddy's SubQ sumatriptan approved

    by dlhnj Feb 2, 2016 10:48 PM
    nammuang nammuang Feb 2, 2016 11:15 PM Flag

    It's an NDA not a generic ANDA as ATRS/Teva Sumatriptan

  • Reply to

    Apple is in; Hobbs is Gone

    by brunoq_78242 Jan 26, 2016 8:18 AM
    nammuang nammuang Jan 26, 2016 8:34 AM Flag

    That is good news.

  • Reply to

    Is ATRS ever going to rise again?

    by rahulbak63 Nov 19, 2015 10:42 AM
    nammuang nammuang Nov 19, 2015 11:12 AM Flag

    rahuwhatever,
    If you are not comfortable with the company,pipeline,management,posters....etc....
    Then you should probably go and find another stock and board to post on. Since you are obviously wasting your own time here.

  • One final under-$10 specialty pharmaceutical player that's starting to spike within range of triggering a major breakout trade is Antares Pharma (ATRS - Get Report) , which that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. This stock has been hit hard by the sellers over the last six months, with shares falling big by 41.1%.

    If you take a glance at the chart for Antares Pharma, you'll notice that this stock has been downtrending badly over the last six months, with shares falling sharply off its high of around $2.50 a share to its new 52-week low of $1.22 a share. During that downtrend, this stock has been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of Antares Pharma spiked modestly higher on Wednesday right above some near-term support at $1.28 a share with monster upside volume flows. Volume for that day registered over 3.76 million shares, which is easily above its three-month average action of 818,214 a shares. That high-volume spike to the upside is now quickly pushing this stock within range of triggering a major breakout trade above some key near-term overhead resistance levels.

    Traders should now look for long-biased trades in Antares Pharma if it manages to break out above its 20-day moving average of $1.35 a share and then above more key resistance levels at $1.40 to its 50-day moving average of $1.48 a share and then over $1.51 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 818,214 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.71 to $2.03, or even its 200-day moving average of $2.09 to $2.25 a share.

    Must Read: 5 Energy Stocks to Buy to Fuel Your Portfolio

    Traders can look to buy shares of Antares Pharma off w

  • Reply to

    andre_y_mb posts this message to blues Today

    by nammuang Nov 27, 2015 8:21 PM
    nammuang nammuang Nov 27, 2015 8:28 PM Flag

    By the way they are still winners but I guess andre did not post to sell at the peak, then he should not use the peak numbers to highlight his excellence.

  • Reply to

    MYL raised EpiPen price 15% on Nov 23.

    by andre_y_mb Dec 1, 2015 10:58 PM
    nammuang nammuang Dec 1, 2015 11:12 PM Flag

    And that means they still Expect EPI from TEVA.
    They would not poke FDA in the Eye with a burning stick if they do not expect serious competition.

  • nammuang by nammuang Jan 22, 2016 4:26 AM Flag

    Tayppy posts what once every three weeks on average and he points out what he believes is the positive potential of the company's portfolio.
    And a whole bunch of posters gets their knickers in a twist.
    Others post daily the same negative rehash of the same issue they have, with less variety than daviscupper and he's endless trivia, but he can actually be funny on occasion and at least he tries to vary his one liners.
    And everyone seems ok with that?
    Then again, it's the same knickers that gets in a twist that also seems to be most eager to re-hash their own negative opinion.

  • That's what you call a flying start.

  • Manipulation works both ways. I hope that this upward one at 5 cents a day will be sustained for a while :o)

  • nammuang nammuang Feb 5, 2016 8:45 PM Flag

    And the conclusion is
    ""Thus, current evidence suggests that the choice of MTX route of administration is a fundamental
    parameter for optimizing RA treatment. The SC route of administration seems to be the best
    treatment option from the outset, in terms of risk:benefit ratio compared with the oral route.
    Finally, although to date there are no real evidence of cost-effectiveness of MTX SC versus
    MTC OR, it is possible to assume that delaying the use of more aggressive and more expensive
    therapies, such as bDMARDs, by switching from MTX OR to MTX SC in non-responders might
    provide cost savings while reducing risks, with relevant implications in the everyday clinical
    care of patients with RA. In this regard, a specifically designed study to assess this
    outcome would be desirable.""

  • Reply to

    Sanofi Auvi-Q Recall

    by nammuang Nov 15, 2015 4:28 AM
    nammuang nammuang Nov 15, 2015 10:08 AM Flag

    icantrade,
    Are you suggesting that one injector can pass on it's flaws to other types of injectors(like influenza). If that is the case FDA will have to take a closer look at the current Mylan injector and every other injector on the market. In fact they better ban all injectors at once just in case.......

  • nammuang nammuang Nov 28, 2015 11:26 PM Flag

    Whogo,
    How do we know that? Are you the seer here?
    The guy said he suspects that FDA will issue a CRL in December to buy some more time due to their backlog.
    But he does not know if they will, how do you know?
    Not because there are any outstanding issues, I think Teva has reiterated the fact that there are no outstanding EPI issues on presentation made after the CC.

ATRS
0.9149+0.0049(+0.54%)Feb 12 3:59 PMEST